ISSN 2689-0852

BIOTECHNOLOGY KIOSK

VOLUME 4, ISSUE 1
JAN 2022



Polymorphism in malaria parasite

www.biotechkiosk.com

Biotechnology Kiosk

www.biotechkiosk.com

Executive Publishers

Megha Agrawal, PhD

(Biotechnology)

Publisher and Editor

Expertise:

Neuroscience, Stroke, Pharmacology, Toxicology, Microbiology, Antiaging, Gene Therapy and Immunology

Email: megha@biotechkiosk.com
meghaagra@gmail.com

Shyamasri Biswas, PhD

(Biotechnology)

Publisher and Editor

Expertise:

Structural Biology, Enzyme Technology, Protein Crystallography, Molecular Biology and Mass Spectrometry

Email: shyabiswas@biotechkiosk.com
shyabiswas@gmail.com

Editorial, Sales & Circulation Office

1330 NW 6th Street
Suite A2, Gainesville
FL-32601, USA
Phone: 386-518-9411
Email: usappg22@gmail.com
publisher@biotechkiosk.com

www.biotechkiosk.com
ISSN 2689-0852
One stop shop for all things biotech

From the Publisher's Desk

Welcome to Biotechnology Kiosk!

The January'2022 issue of BK is now live for our readers with the regular features. This issue includes a research article and editor picks along with a popular article.

We hope our readers will enjoy reading these news and views on the current cutting-edge topics that include latest research breakthroughs in different areas of medicine and biotechnology.

We look forward to receiving your feedback. We do hope that you will enjoy reading this issue of Biotechnology Kiosk. Please do write to us with your comments. Your suggestions are always appreciated.

Dr. Megha Agrawal & Dr. Shyamasri Biswas.

Editors-in-Chief, Biotechnology Kiosk

Contents

Volume 4, Issue 1 Jan 2022

Biotechnology Kiosk

www.biotechkiosk.com

Sequence polymorphism within erythrocyte binding domain of EBA175 in Indian and African field isolates

Monal Sharma[1*], Shailja Singh[2]

International Centre for Genetic Engineering and Biotechnology (ICGEB), NEW Delhi, India

Abstract

Invasion of erythrocyte by Plasmodium merozoites is mediated by specific molecular interactions between proteins expressed on merozoite surface and the receptors present on erythrocytes. Erythrocyte binding antigen 175 (EBA175) is one such protein that interacts with the sialic acid residues on glycophorin A present on erythrocytes' surface during invasion. The FII region (PfFII) of EBA175 has been mapped to be critical for binding to erythrocytes. It is reported that antibodies against FII region blocks binding. Polymorphisms in FII region of EBA175 are already reported. The goal of this study was to investigate whether polymorphism in FII region of African P. falciparum field isolates has any effect on erythrocyte binding and also to find whether antibodies raised against FII region from P. falciparum Malayan Camp strain (Camp) can inhibit erythrocyte binding. Genomic DNA of parasites from the blood samples of P. falciparum infected individuals was isolated and PfFII region from these genomic DNA were amplified, cloned and sequenced. Following sequence analysis, we selected three isolates harboring higher PfFII polymorphisms, expressed them on the surface of COS cells as chimeric proteins using secretory signal and transmembrane segments of Herpex simplex virus glycoprotein D (HSVg D) and tested for their erythrocyte binding ability. We further tested the inhibition of erythrocyte binding of these polymorphic FII regions using anti-campPfF2 antibodies. Our results reveal that the polymorphisms in different field isolates included in this study do not have any significant effect on erythrocyte binding and antibodies raised against FII region of camp strain could inhibit erythrocyte binding by all the polymorphic PfFII. This observation strengthens the possibility that PfFII can be a potential candidate vaccine.

Keywords: Diversity, EBA175, PfFII, Field isolate, Polymorphism.

* Corresponding author: Dr. Monal Sharma
E-mail address: mons2179@gmail.com
DOI: https://doi.org/10.37756/bk.22.4.1.1
[1]Current affiliation: Betterhumans, Inc., 3653 NE 77 Ave, Gainesville, FL 32609, USA
[2]Current affiliation: Jawahar Lal Nehru University, New Delhi, India
Article type: *Mini-article*
Received: *November 21, 2021*
Revised: *December 15, 2021*
Accepted: *December 20, 2021*

Please cite this article as: *Sharma M, Sequence polymorphism within erythrocyte binding domain of EBA175 in Indian and African field isolates, Biotechnol. kiosk, Vol 4, Issue 1, PP: 1-9 (2022); DOI: https://doi.org/10.37756/bk.22.4.1.1*

Introduction

Invasion of erythrocyte by Plasmodium merozoites is mediated by specific molecular interactions between molecules expressed on merozoite surface and the receptors present on erythrocytes [1-3]. Erythrocyte binding antigen 175 (EBA-175) of *Plasmodium falciparum* is one such merozoite surface protein that interacts with the sialic acid residues on glycophorin A present on erythrocytes' surface during invasion [4-6]. EBA-175 is localized in the micronemes at the apical end of the merozoites [7]. The gene encoding EBA-175 consists of an N terminal signal sequence, a long extracellular hydrophilic domain, a transmembrane sequence and a short C terminal cytoplasmic domain [8]. The extracellular domain contains 5' and 3' cysteine rich regions. The 5' cysteine rich region contains two copies named FI and FII [9]. EBA-175 belongs to Duffy binding like erythrocyte binding protein family, because it shares sequence homology with members of this family [10]. The FII region (PfFII) of EBA-175 has been shown to be critical for binding to erythrocytes [11]. The antibodies against FII region block interaction between PfFII and erytrocytes-suggesting that PfFII is a potential vaccine candidate [10]. We investigated polymorphisms in FII region of African *P. falciparum* field isolates by PCR and found that antibodies raised against FII region from the *P. falciparum* Malayan Camp strain can inhibit erythrocyte binding by the field isolates having polymorphism.

Methods

DNA Isolation form filter paper

Genomic DNA of African *P. falciparum* field isolates was extracted from filter paper using the methanol fixation and heat extraction method [12]. Briefly, two-three pieces of filter paper was incubated with 500 µl of methanol for 15 min at room temperature. The methanol was drained off and the papers heated at 95-100°C in 50 µl of sterile distilled water for 15 minutes of incubation with intermittent vortexing. The samples were centrifuged and the final supernatant used as a template for the amplification reaction.

PCR amplification and sequence analysis of FII region of *P. falciparum*

Nested PCR technique was used to amplify gene fragment, which encodes for FII region of *P. falciparum* as described previously [12]. Briefly, for primary PCR reaction, primers EBARIIF (5'ggaagaaatacttcatctaataacg 3') and EBARIIR (5'cgaagtttgttcattatttcttattatag 3') were used and PCR product of primary PCR reaction was used as template for nested PCR with primers EBARIIF2 (5' ttgatttagatgatttttctaaatttg 3') and EBARIIR. The amplified PCR products were resolved on agarose gel (1.0%). PCR product was gel purified, ligated in pGEMT-E vector (Promega) and

transformed in *E. coli* DH10B cells by $CaCl_2$ heat shock method. Two clones of each field isolates, containing inserts were sequenced with T7 promoter, M13R and an internal primer by the cycle sequencing method using Big dye terminator kit (Applied Biosystem) and an ABI prism 310 automated DNA sequencer (Applied Biosystem). Analysis of sequence of FII region of field isolates was done using DNA- Star.

MSP typing of field isolates

PCR typing of these field isolates was done using a highly polymorphism markers, MSP1 and MSP2 as described in [14-15]. The Multiplicity of infection was estimated by the number of PCR fragments per infected individual.

Erythrocyte binding assay

To study the impact of point mutations on binding specificity of region II of P. falciparum field isolates, we chose three field isolates, which harbored more mutations in comparison to Indian field isolates. SE011/2, C032/5, C034/2 have seven, four and seven mutations respectively. These mutants and EBA-175 from CAMP strain were expressed on the surface of COS cells as chimeric proteins using secretory signal and transmembrane segments of Herpex simplex virus glycoprotein D (HSVg D) as described by [7, 16-17]. Surface expression of the chimeric protein on COS cells was determined by immuno-fluorescence using mAb DL6 against proline rich region of HSVgD and anti-mouse Ig-G labeled with FITC (Sigma). Transfected COS cells were incubated with untreated and enzyme (trypsin and neuraminidase) treated erythrocyte (10% hematocrit). Rosettes were scored in 20-25 fields at 40 X magnification.

Erythrocyte binding inhibition assay

Transfected COS cells were incubated with different dilutions (from 1:100 to 1:3200) of anti PfF2 antibodies for 1 hr at 370C and followed by 10% hematocrit. 10 –20 fields were scored for numbers of COS cells with adherent erythrocyte (rosettes) for control and test antibodies against region II of P. falciparum. In presence of different dilutions of anti-PfF2 antibodies, binding pattern was expressed relative to binding in presence of pre immune sera. Pre-immune sera (prior to immunization with PfF2) was used as a control at 1:100 dilution.

Results and Discussion

Diversity in PfFII region of field isolates

We observed 1 Kb amplified product in all field isolates. Region II was present in all field isolates of *P. falciparum*. Analysis of amino acid sequence of FII region from field isolates (Table 1) was showed that more than 98%. Sequence identity. All the cysteines and the positions of these cysteine residues in region II were also conserved. Another interesting observation was

that all field isolates revealed polymorphisms at 15 amino acid positions when compared to the FII amino acid sequence of *P. falciparum* Malayan Camp and Indian field isolates. The present study identified 8 novel polymorphisms. In addition to the 8 novel polymorphisms, sequence diversity at seven positions namely 478, 481, 577, 584, 592, 664 and 716 were commonly present in African and Indian field isolates, which are already reported [18-19]. The non-conservative polymorphisms Asn (N) ↔ Lys (K), Ile (I) ↔ Lys (K), Lys (K) ↔ Gln (Q), Glu (E) ↔ Ala (A), Ser (S) ↔ Arg (R) were found in multiple isolates. And other polymorphisms were present in only one or two field isolates.

Yang et al and colleague did analysis of the genetic diversity of PfEBA 175 from global isolates and the result of study showed a high level of diversity within the parasite population [20].

Allelic diversity in MSP typing

The population diversity was found in field isolates of *P. falciparum* namely C003, C032, C034, C044 and SE011. Three different patterns of genotype were observed (Table 2). K1 allele of MSP1 gene, 3D7 and FC27 alleles of MSP2 gene were observed in C032 and C034. C044 had K1, MAD20 and RO33 alleles of MSP1 and 3D7 allele of MSP2 gene. C003 and SE011 had K1, MAD20 and RO33 alleles of MSP1 gene and 3D7 and FC27 alleles of MSP2 gene. This suggested that the sampled patients had mixed infection.

Erythrocyte binding of filed isolates

COS cells expressing region II bound normal human erythrocytes but not to enzyme (trypsin and neuraminidase) treated human erythrocytes (Table 3). The specificity of binding of normal and enzyme treated erythrocyte to region II expressed on COS cells was identical in native EBA-175 and *P. falciparum field* isolates [21]. From these experiments we conclude that region II of EBA-175 derived from *P. falciparum* field isolates binds erythrocyte with the same specificity as native EBA-175 despite the presence of polymorphic sequences.

To evaluate the relative binding efficiency of variants, we measured inhibition of erythrocytes binding to region II expressed on COS cells with anti PfF2-antibodies. 70% inhibition was observed in all variants by anti-PfFII antibodies (figure 1). The result showed that antibodies against region II of *P. falciparum* inhibit invasion of erythrocytes in vitro and thus provides strong support for developing human vaccine based on region II of *P.falciparum*.

Table 1: Comparison of sequences of F2 region of EBA-175 derived from different *P. falciparum* isolates.

AA no	466	469	478	481	498	507	526	555	567	577	582	584	589	592	614	620	622	625	631	637	650	655	657	663	664	669	716	722
Camp	S	T	N	I	L	K	I	G	K	K	N	K	F	E	V	I	N	Q	S	Y	V	K	C	K	S	Y	E	N
IND			i/k	k	F			e	i	n	d	q/e	S	a	f	I	h		i/r	h			r	r	r	f	k	
SE10			K	K						N		Q		A														
C010			K	K						N		Q													R			
C077			K	K						N		Q													R			
C044-12			K	R			V					Q						N							R			
C044-13			K	K			I					Q													R			
SE015			K	K						N		Q													R			
SE005			K	K						N		E		A														
SE019			K	K						N		Q																
SE011-2			K	K						N		Q						R				R			R			
SE011-5			K							N															R			
C034-2	P		K			Q																						D
C034-3			K																									
C032-2			K	K						N		E		A													K	
C032-5		S	K	K						N		E		A													K	
C003-15			K	K						N		Q		E											R			
C003-18			K	K						N		E		A							A							
SE013																												
CO33-7												Q													R			
CO33-9			K	K								Q																
SE021			K	K								Q													R			

* Red color indicates field isolates which harboring higher mutations and used for further studies.

Table 2: Population diversity in field isolates of P. falciparum.

ALLELE \ ISOLATES		C003	C032	C034	C044	SE011
	K1	+	+	+	+	+
MSP1	MAD20	+	-	-	+	+
	R033	+	-	-	+	+
MSP2	3D7	+	+	+	+	+
	FC27	+	+	+	-	+

(+) indicates: Presence of allele and (-): absent of allele

Table 3: Binding of region F2 derived from EBA-175 from P. falciparum field isolates to normal and enzyme-treated human erythrocytes.

Isolates	AA polymorphism[1]	No Treatment	Enzyme Treatment[2] Neuraminidase	Trypsin
Camp	NA	+	-	-
SE011/2	7	+	-	-
C032/5	7	+	-	-
C034/2	4	+	-	-

[1]Number of differences in amino acid sequence of region F2 from *P. falciparum* field isolates compared to amino acid sequence of region F2 of EBA-175 derived from *P. falciparum* Camp strain.

[2]COS 7 cells transfected to express region F2 from diverse *P. falciparum* isolates were tested for binding to normal and enzyme-treated human erythrocytes. The number of COS 7 cells covered with rosettes of adherent erythrocytes was scored in 15 random fields at 40X magnification. +, denotes that adherent rosettes were observed. -, indicates that no rosettes were seen in the entire well used for transfection and binding assays.



Fig. 1: Inhibition of binding of erythrocytes to region F2 of EBA-175 from diverse P. falciparum field isolates using rabbit sera raised against region F2 of EBA-175 from P. falciparum Camp strain. COS 7 cells transfected to express region F2 of EBA-175 derived from P. falciparum Camp strain and diverse *P. falciparum* field isolates (SE011/2, C034/2 and C032/5) were tested for binding to human erythrocytes in presence of rabbit sera raised against recombinant region F2 of EBA-175 from *P. falciparum* Camp strain. Binding in presence of pre-immune serum (1:100 dilution) was used as control. Number of rosettes of adherent erythrocytes was scored in 20 fields at 400× magnification. Number of rosettes in presence of anti-F2 sera is shown relative to number of rosettes of adherent erythrocytes in presence of pre-immune sera.

Conclusion

Erythrocyte binding antigen 175 (EBA-175) of Plasmodium falciparum belongs to Duffy binding like erythrocyte binding protein family. It contains three cysteine-rich regions F1, F2 and C in which F1 and F2 at the N-terminus are responsible for the glycophorin A binding on the erythrocyte membrane. The FII region (PfFII) of EBA-175 has been shown as a potential vaccine candidate. We investigated polymorphisms in FII region of African P. falciparum field isolates by PCR and found that antibodies raised against FII region from the P. falciparum Malayan Camp strain can inhibit erythrocyte binding by the field isolates having polymorphism. Our findings suggest that antibodies to region II of EBA-175 are largely unaffected by polymorphism in EBA-175 and is a good ligand-blocking malaria vaccine.

Authors' contributions

Conceived and designed experiments: MS, SS. Performed the experiments: MS, and SS. Analyzed the data: MS, SS. Wrote the paper: MS, SS. Involved in all the experiments: MS and SS.

Acknowledgement

This work has been funded by DBT India. SS is a recipient of the IYBA Award from DBT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Hardley TJ, Klotz FW, Miller LH, Invasion of erythrocytes by malaria parasites, a cellular and molecular overview. Annu Rev Microbiol 1986, 40:451-477. DOI: https://doi.org/10.1146/annurev.mi.40.100186.002315
2. Cowman AF, Berry D, Baum J, The cellular and molecular basis for malaria parasite invasion of the human red blood cell. JCB 2012, 198: 961-971. DOI: https://doi.org/10.1083/jcb.201206112
3. Guar D, Chitnis CE, Molecular interactions and signaling mechanisms during erythrocyte invasion by malaria parasites. Curr opin Microbiol 2011, 14:422-428. DOI: https://doi.org/10.1016/j.mib.2011.07.018
4. Klotz FW, Orlandi PA, Reuter G, Cohen SJ, Haynes JD, Schauer R, Howard RJ, Palese P, Miller LH, Binding of Plasmodium falciparum 175-kilodalton erythrocyte binding antigen and invasion of murine erythrocytes requires N-acetylneuraminic acid but not its O-acetylated form. Mol Biochem Parasitol 1992, 51:49-54. DOI: https://doi.org/10.1016/0166-6851(92)90199-T
5. Orlandi PA, Klotz FW, Haynes JD, A malaria invasion receptor, the 175-kilodalton erythrocyte binding antigen of Plasmodium falciparum recognizes the terminal Neu5Ac (alpha 2-3) Gal- sequences of glycophorin A. J

Cell Biol 1992, 116:901-909. DOI: https://doi.org/10.1083/jcb.116.4.901

6. Ambroggio X, Jiang L, Aebig J, Obiakor H, Lukszo J, Narum DL, The Epitope of Monoclonal Antibodies Blocking Erythrocyte Invasion by Plasmodium falciparum Map to The Dimerization and Receptor Glycan Binding Sites of EBA-175. PLOS One 2013, 8: e56326. DOI: https://doi.org/10.1371/journal.pone.0056326
7. Sim BK, Chitnis CE, Wasniowska K, Hadley TJ, Miller LH, Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. Science. 1994, 264:1941-1944. DOI: https://doi.org/10.1126/science.8009226
8. Adams JH, Kaneko O, Blair PL, Peterson DS, An expanding ebl family of Plasmodium falciparum. Trends Parasitol. 2001, 17:297-299. DOI: https://doi.org/10.1016/S1471-4922(01)01948-1
9. Adams JH, Sim BK, Dolan SA, Fang X, Kaslow DC, Miller LH, A family of erythrocyte binding proteins of malaria parasites. Proc Natl Acad Sci U. S. A. 1992, 89:7085-7089. DOI: https://doi.org/10.1073/pnas.89.15.7085
10. Sim BK, Orlandi PA, Haynes JD, Klotz FW, Carter JM, Camus D, Zegans ME, Chulay JD: Primary structure of the 175K Plasmodium falciparum erythrocyte binding ntigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion. J Cell Biol 1990, 111:1877-84. DOI: https://doi.org/10.1083/jcb.111.5.1877
11. Camus D, Hadley TJ, A Plasmodium falciparum antigen that binds to host erythrocytes and merozoites. Science 1985, 30: 553-556. DOI: https://doi.org/10.1126/science.3901257
12. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems E, Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 1995, 52:565-568. DOI: https://doi.org/10.4269/ajtmh.1995.52.565
13. Mamillapalli A, Pattnaik P, Sharma M, Sharma SK, Tyagi PK, Joshi H, Chitnis CE, Sequence polymorphisms in the receptor-binding domain of Plasmodium falciparum EBA-175: Implications for malaria vaccine development. Mol Biol Parasitol 2006, 146: 120-123. DOI: https://doi.org/10.1016/j.molbiopara.2005.09.019
14. Ntoumi F, Contamin H, Rogier C, Bonnefoy S, Trape JF, Mercereau-Puijalon, O. Age-dependent carriage of multiple Plasmodium falciparum merozoite surface antigen-2 alleles in asymptomatic malaria infections. Am J Trop Med Hyg 1995, 52:81-88. DOI: https://doi.org/10.4269/ajtmh.1995.52.81

15. Robert F, Ntoumi F, Angel G, Candito D, Rogier C, Fandeur T, Sarthou JL, Mercereau-Puijalon O, Extensive genetic diversity of Plasmodium falciparum isolates collected from patients with severe malaria in Dakar, Senegal. Trans R Soc Trop Med Hyg 1996, 90:704-711. DOI: https://doi.org/10.1016/S0035-9203(96)90446-0
16. Cohen GH, Wilcox WC, Sodora DL, Long D, Levin JZ, Eisenberg RJ, Expression of herpes simplex virus type 1 glycoprotein D deletion mutants in mammalian cells. J Virol 1988, 62:1932–1940.DOI: https://doi.org/10.1128/jvi.62.6.1932-1940.1988
17. Chitnis CE, Miller LH, Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. J Exp Med 1994, 180:497-506. DOI: https://doi.org/10.1084/jem.180.2.497
18. Baum J, Thomas AW, Conway DJ, Evidence for diversifying selection on Erythrocyte-binding antigens of Plasmodium falciparum. Genetics 2003, 163:1327-1336. DOI: https://doi.org/10.1093/genetics/163.4.1327
19. Liang H, Sim BK, Conservation of structure and function of the erythrocyte binding domain of Plasmodium falciparum EBA-175. Mol. Biochem. Parasitol. 1997, 84:241-245. DOI: https://doi.org/10.1016/S0166-6851(96)02791-0
20. Yang, PK., Liang, XY., Lin, M. et al. Population genetic analysis of the Plasmodium falciparum erythrocyte binding antigen-175 (EBA-175) gene in Equatorial Guinea. Malar J 20, 374 (2021). DOI: https://doi.org/10.1186/s12936-021-03904-x
21. Orlandi PA, Sim KL, Chulay JD, Haynes JD, Characterization of the 175 Kd erythrocyte binding antigen of Plasmodium falciparum. Mol. Biochem. Parasitol. 1990, 40:285–294. DOI: https://doi.org/10.1016/0166-6851(90)90050-V

Popular Article

Benefits Your Employees Will Love

Lance Cody-Valdez

A robust and innovative benefits package is critical in today's job market. Employees want more than just a paycheck from their employers; they're looking for meaningful benefits that will enhance their lives and make them feel valued. If you're an employer looking for new ways to stand out against the competition, Biotechnology Kiosk shares some of the most innovative ways you can offer benefits to your team.

Think "People First"

Having a strong benefits package for employees is essential in attracting and retaining talented team members. A robust compensation package, including salary, medical, and retirement plans, help demonstrate to your employees how important they are to the organization. Not only does offering a comprehensive benefits package show your commitment to the well-being of your staff, it communicates that you are invested in their professional development and long-term success. Investing in this type of "people capital" can ultimately result in increased loyalty, productivity, and improved retention rates.

Support Education

Education benefits are a great way for employers to encourage their employees to stay with the company. Investing in tuition reimbursement or certification funding can offer your workforce the opportunity to upskill and stay ahead of the competition.

Everyone benefits when you empower your employees to take control of their own development. Growth helps your team members and allows your company to become more efficient. Go here today to discover online classes that will unlock new potential and help propel your organization toward success.

Encourage Fitness

Encouraging physical activity is another great way to provide health and wellness benefits for your staff. Some employers offer gyms at their workplaces, while others provide gym memberships and yoga classes for their employees to give them access to fitness activities outside of work hours. This helps promote healthy lifestyles, which can lead to increased productivity at work.

Promote Healthy Eating

Nutrition services like meal delivery or free snacks at work are becoming increasingly popular among employers as a way to ensure that their staff has access to healthy meals throughout the day. This type of benefit encourages healthier eating habits and helps boost morale by showing employees that they are

valued and cared for by their employers. Additionally, research shows that improved nutrition leads to better workplace performance, so this could be a win-win situation all around.

Prioritize Mental Health

Employee mental health should always be a priority for employers. Offering counseling services can help improve employee morale by providing support for those dealing with difficult life situations or stress-related issues. This benefit can also help reduce employee turnover by making sure staff are taken care of both inside and outside of work hours.

Ask for Feedback

Surveying employees annually is a great way to stay connected with the team. It allows your organization to understand the morale of our workforce and make changes that can foster a positive work environment. Gathering feedback from employees helps create more job satisfaction, improves communication between leadership and personnel, and increases productivity for all stakeholders.

Employers who understand how important it is to offer innovative benefits packages will be well positioned in today's job market when it comes time to recruit new talent or retain existing team members. By offering education benefits, fitness memberships, counseling, and more, employers can create a happier workforce with higher morale, which ultimately leads to increased productivity within the organization.

Image via Pexels.

Biotechnology Advances around the World

Editor's Picks

Every issue of Biotechnology Kiosk presents select latest research news picked by the editors-in-chief on significant research breakthroughs in different areas of biotechnology around the world. The aim is to promote further R&D in all of these cutting-edge areas of biotechnology. The editors have compiled and included the following innovations and breakthroughs to highlight the latest biotechnology advances.

Dr. Megha Agrawal
Co Editor-in-Chief

Dr. Shyamasri Biswas
Co Editor-in-Chief

Food Packaging

Identification of sesame in food packaging

Food borne allergy is a common problem. Studies have shown that sesame is the ninth most common childhood food allergy in the US. However, there is not enough public awareness to recognize it on food labels. Some food labels entirely miss mentioning about sesame.

To address the issue of sesame induced food allergy, researchers in the US conducted a new study that was published in Annals of Allergy, Asthma and Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI). They found that among those who self-reported an allergic reaction to sesame, more than 56% of products which contained sesame did not declare sesame on the label (Adverse Events and Labeling Issues Related to Suspected Sesame Allergy Reported in an Online Survey. Annals of Allergy, Asthma & Immunology, 2021; DOI: https://doi.org/10.1016/j.anai.2021.12.005).

In this study, they discovered that amongst those who reported events related to accidental ingestion of sesame, many reported they didn't know that words such as 'tahini' meant sesame. This is due to the reason that the word 'sesame' is often not used on labels, and therefore, accidents happen at a greater rate.

Researchers in the study examined 379 self-reported events related to sesame involving 327 individuals with 360 distinct adverse clinical reactions. They reported that 19 events involved a sesame labeling issue that did not result in a clinical reaction. Most of the reports (85%) were from parents providing information on events with their children. Finally, the authors concluded that it was critical to provide clear and specific product labeling for sesame. This can help prevent adverse reactions, especially anaphylaxis, in food-allergic people.

Linking air pollution to physical activities and subsequent effects on brain and aging

Researchers in the United States showed in a new study that people doing vigorous physical activities such as jogging or playing competitive sports in areas with higher air pollution could end up with less benefit from that exercise when it comes to certain markers of brain disease. Researchers examined the markers included white matter hyperintensities, which indicated injury to the brain's white matter, and gray matter volume. Larger gray matter volumes and smaller white matter hyperintensity volumes were markers of overall better brain health. The research was published in the December 8, 2021, online issue of Neurology®, the medical journal of the American Academy of Neurology (Association of Air Pollution and Physical Activity With Brain Volumes. Neurology, 2021; 10.1212/WNL.0000000000013031, DOI: https://doi.org/10.1212/WNL.0000000000013031).

Theoretically, vigorous exercise could increase exposure to air pollution and some prior studies showed adverse effects of air pollution on the brain. In this study, researchers examined physical activity tha was associated with improved markers of brain health in areas with lower air pollution. However, they observed disappearing beneficial effects for vigorous physical activity in areas with the highest levels of air pollution. They found that the effect of air pollution on brain health was modest roughly equivalent to half the effect of one year of aging. On the other hands, the effects of vigorous activity on brain health were found to be much larger that was approximately equivalent to being three years younger.

This study was conducted with 8,600 people with an average age of 56 from the UK Biobank, a large biomedical database. Subsequently, people's exposure to pollution, including nitrogen dioxide and particulate matter (particles of liquids or solids suspended in the air) was estimated with land use regression. A land use regression study models showed air pollution levels based on air monitors and land use characteristics like traffic, agriculture and industrial sources of air pollution.

Compiled and Edited by Dr. Megha Agrawal and Dr. Shyamasri Biswas.


VACUUM TECHNOLOGY & COATING
Claim Your Free Digital Subscription to VT&C
Vacuum Technology & Coating Magazine has been the only publication dedicated exclusively to the Vacuum Processing and Thin Film Deposition industries since it was founded in 2000.
Each monthly issue includes columns focused on Thin Film Deposition, Vacuum Processing, Characterization of Thin Films, Nanotechnology and Biotechnology, often with guest editorial by scientists and manufacturers in the industry.
Monthly Product Showcases introduce the latest products with a wide range of topics including: Deposition and Coating Equipment, Furnaces, Ovens, Chillers and Cryosystems, Vacuum Hardware, Gas Handling and Gas Analytical Systems, Measurement and Metrology, Materials, and Vacuum Pumps, and many more.
Subscribe to Vacuum Technology & Coating Magazine Today!
Print or Digital
http://www.vtcmag.com/subscribe.html
vacuum TECHNOLOGY & coating
www.vtcmag.com

For all production related questions or sending your ads, please e-mail or call our production department: E-mail: sales@biotechkiosk.com; Phone: 386-518-9411.

THANK YOU!